NVO
Another Wegovy victory lap
Novo Nordisk is back with fresh sub-analyses from its STEP UP trial, and the headline is simple: the higher 7.2 mg dose of Wegovy kept delivering the goods. People with obesity who took the stronger dose lost about 21% of their body weight over 72 weeks, versus roughly 17.5% for the standard 2.4 mg dose and 2.4% for placebo.
That’s the kind of data drugmakers dream about — the sort that makes doctors nod, patients squint at the scale, and investors wonder if the next leg higher is already baked in.
Fat loss, not just “weight” loss
Novo also said the weight coming off was mostly body fat. In a separate MRI-based analysis, about 84% of the loss was tied to fat mass, while muscle function stayed intact on a sit-to-stand test.
That matters because the GLP-1 conversation has started to evolve from “How much weight did you lose?” to “What exactly came off?” If you can keep the muscle while melting the spare tire, that’s a much cleaner pitch for both regulators and patients.
Why investors should care
The bigger picture is that Novo keeps adding ammo to the Wegovy story at a time when the stock has been trading near recent lows. Strong efficacy data helps defend the company’s obesity franchise, especially as the market keeps asking whether the GLP-1 party is getting crowded.
- The higher dose looked more effective without a new safety curveball.
- Early responders did especially well, which adds another layer to how clinicians might think about dosing.
- Novo still needs to turn good science into durable commercial momentum, because Wall Street is rude and asks for sales, not just slide decks.
Big picture: if Wegovy is the engine, this is Novo showing the turbo button still works.